S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

BioCryst Pharmaceuticals Stock Forecast, Price & News

+0.59 (+5.80%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
6.85 million shs
Average Volume
3.06 million shs
Market Capitalization
$2.00 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BCRX Stock Forecast (MarketRank)

Overall MarketRank

2.35 out of 5 stars

Medical Sector

233rd out of 1,417 stocks

Biological Products, Except Diagnostic Industry

34th out of 216 stocks

Analyst Opinion: 4.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
BioCryst Pharmaceuticals logo

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
$-184.06 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$157.17 million
Book Value
($0.60) per share


Free Float
Market Cap
$2.00 billion

Social Links

BioCryst Pharmaceuticals Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BioCryst Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCRX, but not buy additional shares or sell existing shares.
View analyst ratings for BioCryst Pharmaceuticals
or view top-rated stocks.

What is BioCryst Pharmaceuticals' stock price forecast for 2022?

9 Wall Street analysts have issued 1 year target prices for BioCryst Pharmaceuticals' stock. Their BCRX stock forecasts range from $13.00 to $30.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $18.10 in the next year. This suggests a possible upside of 68.2% from the stock's current price.
View analysts' price targets for BioCryst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has BioCryst Pharmaceuticals' stock performed in 2022?

BioCryst Pharmaceuticals' stock was trading at $13.85 on January 1st, 2022. Since then, BCRX shares have decreased by 22.3% and is now trading at $10.76.
View the best growth stocks for 2022 here

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for BioCryst Pharmaceuticals

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.01. The biotechnology company earned $49.92 million during the quarter, compared to analysts' expectations of $50.59 million.
View BioCryst Pharmaceuticals' earnings history

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioCryst Pharmaceuticals own?

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.60%), Vanguard Group Inc. (7.12%), State Street Corp (4.02%), Fisher Asset Management LLC (2.15%), Victory Capital Management Inc. (1.91%) and Loomis Sayles & Co. L P (1.27%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends for BioCryst Pharmaceuticals

Which major investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, State Street Corp, BlackRock Inc., Deerfield Management Company L.P. Series C, Granahan Investment Management LLC, UBS Group AG, Citigroup Inc., and Group One Trading L.P.. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last two years include Alane P Barnes, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Nancy J Hutson, William P Sheridan, and Yarlagadda S Babu.
View insider buying and selling activity for BioCryst Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Victory Capital Management Inc., Lord Abbett & CO. LLC, Loomis Sayles & Co. L P, Lisanti Capital Growth LLC, Goldman Sachs Group Inc., Ghost Tree Capital LLC, and Renaissance Technologies LLC. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Anthony Doyle, and Vincent Milano.
View insider buying and selling activity for BioCryst Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $10.76.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $2.00 billion and generates $157.17 million in revenue each year. The biotechnology company earns $-184.06 million in net income (profit) each year or ($1.070010) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals employs 358 workers across the globe.

When was BioCryst Pharmaceuticals founded?

BioCryst Pharmaceuticals was founded in 1986.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for BioCryst Pharmaceuticals is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at [email protected], or via fax at 919-859-1314.

This page (NASDAQ:BCRX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.